- Home
- CHNR vs SNGX Comparison
CHNR vs SNGX Comparison
Compare CHNR & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- SNGX
- Stock Information
- Founded
- CHNR N/A
- SNGX 1987
- Country
- CHNR China
- SNGX United States
- Employees
- CHNR N/A
- SNGX N/A
- Industry
- CHNR Precious Metals
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- SNGX Health Care
- Exchange
- CHNR Nasdaq
- SNGX Nasdaq
- Market Cap
- CHNR 5.5M
- SNGX 6.5M
- IPO Year
- CHNR 1995
- SNGX 1987
- Fundamental
- Price
- CHNR $0.59
- SNGX $1.93
- Analyst Decision
- CHNR
- SNGX
- Analyst Count
- CHNR 0
- SNGX 0
- Target Price
- CHNR N/A
- SNGX N/A
- AVG Volume (30 Days)
- CHNR 72.8K
- SNGX 18.1K
- Earning Date
- CHNR 05-15-2025
- SNGX 05-09-2025
- Dividend Yield
- CHNR N/A
- SNGX N/A
- EPS Growth
- CHNR N/A
- SNGX N/A
- EPS
- CHNR N/A
- SNGX N/A
- Revenue
- CHNR N/A
- SNGX $2,342.00
- Revenue This Year
- CHNR N/A
- SNGX N/A
- Revenue Next Year
- CHNR N/A
- SNGX N/A
- P/E Ratio
- CHNR N/A
- SNGX N/A
- Revenue Growth
- CHNR N/A
- SNGX N/A
- 52 Week Low
- CHNR $0.45
- SNGX $1.68
- 52 Week High
- CHNR $1.13
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- CHNR 57.23
- SNGX 49.95
- Support Level
- CHNR $0.51
- SNGX $1.86
- Resistance Level
- CHNR $0.58
- SNGX $1.97
- Average True Range (ATR)
- CHNR 0.04
- SNGX 0.09
- MACD
- CHNR 0.00
- SNGX 0.01
- Stochastic Oscillator
- CHNR 84.27
- SNGX 70.59
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).